Vizsgálati helyszín
Holy Cross Hospital
Silver Spring, Maryland 20910, Egyesült ÁllamokMég nincs intézményhez kötve
- 10futó vizsgálat
- 13lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult12 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Toboroz2 vizsgálat
- Felfüggesztve1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)6 vizsgálat
- SWOG Cancer Research Network3 vizsgálat
- Radiation Therapy Oncology Group2 vizsgálat
- AbbVie1 vizsgálat
- Acrivon Therapeutics1 vizsgálat
- és még 11
Futó vizsgálatok
Toboroz
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471· 3. fázis· Genelux Corporation· Forrás
Contact: Lyudmila Igorevna Kalnitskaya, MBA, MS
Toboroz
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257· 1. fázis· Bio-Path Holdings, Inc.· Forrás
Contact: Sujana Lalagari
Toboroz
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Jennifer Beeler
Toboroz
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954· 3. fázis· NSABP Foundation Inc· Forrás
Fut, nem toboroz
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752· 2. fázis· Eastern Cooperative Oncology Group· Forrás
Fut, nem toboroz
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
NCT00499330· Alliance for Clinical Trials in Oncology· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296· 2. fázis· Acrivon Therapeutics· Forrás
Contact: Mansoor Raza Mirza, MD
Toboroz
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691· 1/2. fázis· DualityBio Inc.· Forrás
Contact: Britney Winterberger
Lezárult
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· 3. fázis· AbbVie· Forrás
Lezárult
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
NCT02595905· 2. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
NCT01454297· Multiple Myeloma Research Foundation· Forrás
Lezárult
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249· 3. fázis· SWOG Cancer Research Network· Forrás
Lezárult
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712· 3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451· 3. fázis· GOG Foundation· Forrás
Lezárult
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936390· 3. fázis· Radiation Therapy Oncology Group· Forrás
Lezárult
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00980954· 3. fázis· Radiation Therapy Oncology Group· Forrás
Lezárult
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900· 3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· 3. fázis· National Cancer Institute (NCI)· Forrás
Hibát jelzek